The ADAURA trial found that patients with stage IB–IIIA, EGFR-mutated NSCLC (n = 682) who received postoperative adjuvant osimertinib had better DFS compared to placebo (four-year DFS: osimertinib 73% vs. placebo 38%) [57]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.